Croda International Plc: history, ownership, mission, how it works & makes money

From a 1925 Sheffield lanolin start-up to a global specialty-chemicals powerhouse, Croda International Plc (ticker CRDA / Frankfurt 6CMB) has charted a century of strategic growth-listing on the London Stock Exchange in 1964, pursuing landmark deals such as the £410m acquisition of Uniqema in 2006 and the €820m purchase of Iberchem in 2020-and by 2025 celebrating its centenary while operating with over 5,800 employees across 92 locations in 39 countries; guided by the purpose "Smart science to improve lives™," Croda sources around two‑thirds of its organic raw materials from bio‑based origins, aims to be Climate, Land and People Positive by 2030, and combines Consumer Care, Life Sciences and Industrial Specialties to supply premium sustainable ingredients that helped drive a 6.5% sales rise in Q3 2025 and underpin an expected underlying profit range of £265-£295m for the year, all under the governance of Chair Danuta Gray and CEO Steve Foots as it pursues targeted cost savings (£25m in 2025, £100m annualised by 2027) and continued market leadership as Britain's Most Admired Chemicals Company for eight consecutive years.

Croda International Plc (CRDA.L): Intro

• Founded: 1925 (George William Crowe & Henry James Dawe)
• London Stock Exchange listing: 1964
• Key early acquisitions: United Premier Oil (1967), British Glues & Chemicals (1968)
• Notable R&D: Involvement in development of Lorenzo's oil in the 1990s
• Major modern acquisition: ICI's Uniqema for £410 million (2006)
• Centenary: 2025 (100 years of operations)

• 1925-1950s: Core lanolin extraction and foundational growth into cosmetics and industrial lubricants.
• 1960s-1980s: Public listing (1964) and diversification through acquisitions (United Premier Oil 1967; British Glues & Chemicals 1968).
• 1990s: Increased focus on life-science related chemistries; contribution to Lorenzo's oil research for adrenoleukodystrophy treatment.
• 2006: Transformational acquisition of Uniqema (£410m) broadened personal care and specialty ingredient portfolio.
• 2010s-2020s: Steady investment in sustainable technologies, bio-based ingredients, global manufacturing footprint expansion and margins improvement.

• Customer-facing model: B2B supply of finished ingredients and formulation technologies to personal care, health care, crop care and industrial markets.
• R&D-driven: Central labs plus application development centres that co-develop formulations with customers.
• Manufacturing & supply chain: Global manufacturing network with regional distribution to ensure service, regulatory compliance and speed-to-market.
• Sustainability & differentiation: Emphasis on bio-based feedstocks, lifecycle assessments and product stewardship to meet regulatory and customer sustainability targets.

• Product sales: Specialty additives, emollients, surfactants and functional ingredients sold in bulk or as formulated ingredients.
• Customer collaboration & formulation services: Higher-margin co-development and application support.
• Geographic & sector mix: Revenue across personal care, life sciences, crop care and industrial markets reduces cyclicality.
• Pricing & margin management: Value-based pricing tied to performance/differentiation and feedstock management.

• Innovation: Prioritise proprietary, performance-based chemistries and formulation know-how to command premium pricing.
• Sustainability: Shift to bio-based feedstocks, reduce carbon intensity and deliver sustainable product platforms.
• Portfolio balance: Grow higher-margin specialties (personal care, life sciences) while protecting industrial streams.
• M&A & partnerships: Supplement organic R&D with selective acquisitions (historically Uniqema 2006) and strategic alliances.

• Listed entity: Croda International Plc (ticker: CRDA.L) on the London Stock Exchange since 1964; constituent of mid-cap indices.
• Major shareholders: Mix of institutional investors (UK, Europe, North America), pension funds and asset managers; free float supports active trading.
• Dividend policy: Progressive dividend with focus on sustainable payout aligned to earnings and cash generation.

Croda International Plc (CRDA.L): History

• Founded: 1925 (lanolin extraction and refining)
• Transformation: moved from commodity oils to speciality ingredients across cosmetics, pharma intermediates, crop science and industrial additives
• Global footprint: manufacturing and R&D sites across Europe, North America, Asia and Latin America
• Governance milestones: professionalised board and international listings to support global expansion

• Publicly traded: Croda International Plc is listed on the London Stock Exchange under the ticker CRDA and on the Frankfurt Stock Exchange as 6CMB.
• Shareholder mix (late 2025, approximate): institutional investors ~75%, retail/individual ~12%, company insiders and directors ~1-2%, other/nominee accounts ~10-12%.
• Board and leadership: the board comprises experienced international executives - Danuta Gray serves as Chair and Steve Foots as Chief Executive Officer, supported by independent non-executive directors overseeing audit, remuneration and nominations.
• Governance impact: diversified institutional ownership and a strengthened independent board support strategic capital allocation, M&A flexibility and adherence to sustainability-linked targets.

• Business model: high-margin speciality ingredients sold B2B into formulation chains (personal care, pharmaceuticals, crop care, performance technologies).
• Revenue drivers: innovation-led product launches, long-term supplier contracts, formulation partnerships and geographic expansion into faster-growing markets (Asia-Pacific, North America).
• Profit drivers: premium pricing on differentiated chemistries, scale manufacturing, vertical integration of feedstocks and cost-savings from process efficiencies.
• Capital allocation: reinvestment in R&D and sustainable manufacturing, bolt-on acquisitions to access new chemistries or end markets, and shareholder returns via dividends and occasional buybacks.

Croda International Plc (CRDA.L): Ownership Structure

• Mission and values: 'Smart science to improve lives™' underpins R&D-led growth, sustainability and ethical conduct.
• Sustainability: ~66% of organic raw materials are bio‑based; committed to net‑positive impact on climate, land and people by 2030.
• Innovation: ongoing development of proprietary, high‑performance ingredients for multiple end‑markets.
• People and culture: emphasis on inclusivity, diversity and talent retention across c.4,300 employees worldwide.
• Reputation: voted Britain's Most Admired Chemicals Company for eight consecutive years.

• Primary revenue drivers: specialty ingredient sales to personal care, health care, crop solutions and industrial markets; margin enhancement via formulation expertise and proprietary tech.
• Business model: high margin specialty products, long-term customer relationships, technical support and regulatory know‑how create recurring revenue and pricing power.
• Growth levers: sustainable, bio‑based feedstocks, tailored formulations, geographic expansion and bolt‑on acquisitions in adjacent speciality chemistries.

• Publicly listed (LSE: CRDA). Shares held predominantly by institutional investors and asset managers.
• Typical top institutional holders (approximate recent positions): BlackRock (~7.5%), Baillie Gifford (~6.0%), Vanguard (~5.5%), Schroders (~3.8%).
• Free float: high - most equity is held by global institutions rather than a single family or state owner.

Croda International Plc (CRDA.L): Mission and Values

• Consumer Care - beauty care, beauty actives, home care, fragrances and flavours; formulation support and branded actives for personal care companies and retailers.
• Life Sciences - crop care ingredients and adjuvants, healthcare specialty ingredients (excipients, lipid carriers), and biologics drug‑delivery systems and contract development for pharmaceutical customers.
• Industrial Specialties - performance surfactants, phase change materials (thermal storage), and formulated textile and spin finishes for industrial and manufacturing customers.

• Customer engagement - collaboration from concept to scale, with application testing, regulatory dossiers and formulation optimization.
• Manufacturing strategy - multi-site production and strategic licensing to de‑risk supply, combined with targeted capital projects to expand capacity for high‑growth actives.
• Value capture - premium pricing for performance or regulatory-advantaged ingredients and long-term supply agreements with major consumer and agrochemical companies.

• Product mix - higher-margin speciality actives and biologics-related services versus commodity surfactants.
• Customization and formulation services - premium margin for tailored solutions and branded actives.
• Geographic diversification - sales balance across Europe, North America, Asia and emerging markets to capture regional growth and mitigate single‑market risk.

• R&D intensity - sustained investment in chemistry, biology and formulation science to create differentiated actives and delivery systems.
• Regulatory and quality systems - global regulatory dossiers, GMP and supply‑chain compliance that enable pharma, agro and personal care customers to commercialize products in multiple territories.
• Scale for new technologies - targeted capital projects to expand capacity for high-value actives, biologics delivery lipids and sustainable feedstocks.

• Personal care brands - improved sensory performance, stability and efficacy via Croda actives and formulation expertise.
• Agriculture - adjuvants and specialty chemistries that increase pesticide performance and reduce application rates.
• Pharmaceuticals & biologics - excipients and lipid delivery systems for small molecule and mRNA/biotherapeutic formulations.
• Industrial applications - thermal management products (phase change materials) and high-performance surfactants for industrial processes.

Croda International Plc (CRDA.L): How It Works

• Core customer industries: personal care & beauty, pharmaceuticals & biologics, crop protection & seed treatments, lubricants & industrial formulations, coatings and homecare.
• Primary revenue drivers: differentiated ingredient formulation, long-term supply agreements, technical services and licensing of delivery technologies.
• Competitive advantages: proprietary chemistries, strong application development teams, global manufacturing footprint and sustainability credentials (bio-based and recyclable solutions).

• Direct sales of specialty ingredients to manufacturers and brand owners across multiple industries, often embedded into customers' finished products.
• Premium pricing for performance and sustainability benefits-customers are willing to pay more for proven claims (e.g., natural origin, biodegradability, reduced environmental footprint, improved efficacy).
• Higher-margin services: formulation support, regulatory assistance, custom development, and technical training that lock in long-term customer relationships.
• Strategic M&A to broaden portfolio and enter adjacent markets-example: acquisition of Iberchem in 2020 for €820 million to strengthen fragrance and scent technologies.

• Largest contributor: high-margin formulations and active ingredients for skin care, hair care, sun protection and product preservation.
• Value drivers: sustainable, bio-based emulsifiers, emollients and UV filters that support brand claims and regulatory compliance.
• Typical margins: historically the highest of the three segments due to formulation and branding partnership economics.

• Product set: pharmaceutical excipients, delivery systems for biologics, vaccine adjuvants, and crop protection adjuvants and intermediates.
• Revenue characteristics: multi-year contracts with pharma and agrochemical firms, bespoke development work and regulatory-backed demand.
• Growth levers: biologics delivery platforms and increasing demand for sustainable crop inputs in agriculture.

• Includes surfactants, emulsifiers, lubricants, phase change materials, and other industrial additives used in coatings, oil & gas, polymers and homecare.
• Scale-driven: larger volumes but typically lower per-unit price vs. Consumer Care; profitability augmented by proprietary chemistries and application support.

• R&D investment: typically around 4-6% of revenue (c. £60-90m annually in recent years) to maintain product pipeline and technical differentiation.
• Margins: Croda has historically targeted double-digit underlying operating margins (mid‑teens in stronger years), reflecting the specialty, high-value nature of its products.
• Capital allocation: reinvestment in manufacturing and technology scale-up, plus targeted acquisitions (e.g., Iberchem for €820m) to expand market reach and cross-sell capabilities.
• Geographic footprint: global manufacturing and sales network reducing single-market exposure and enabling supply to multinational customers.

• New sunscreen actives or emollients developed by Croda are adopted by multinational personal-care brands and specified into supply contracts-this creates recurring sales and the ability to charge a premium versus commodity oils.
• Life-sciences delivery systems licensed into pharma pipelines lead to milestone payments and long-term supply agreements for clinical and commercial supply.
• Acquisitions like Iberchem broaden the addressable market (fragrance & scent solutions) and enable bundling of ingredients + fragrance offerings to consumer brands, increasing average deal size and cross-sell.

• Innovation-led product launches that command price premium and reduce sensitivity to raw-material commodity cycles.
• Sustainability credentials (bio-based materials, lower carbon footprint) that align with customer and regulatory trends, enabling differentiation and price resilience.
• Global supply-chain investments and regional manufacturing to be close to key customers and manage margin volatility.

Croda International Plc (CRDA.L): How It Makes Money

• Market leadership: Recognised as Britain's Most Admired Chemicals Company for eight consecutive years, supporting pricing power and customer trust.
• Growth engines: Beauty Actives, Fragrances & Flavours, and Crop Protection-Q3 2025 sales rose 6.5% overall, driven primarily by these segments.
• Operational targets: £25m of cost savings targeted for 2025 and a path to £100m annualised savings by 2027, improving margin resilience.

• Revenue model specifics: high-margin proprietary actives and formulation services, recurring supply contracts, and technical support/innovation partnerships that lengthen customer lifetime value.
• Margin improvement levers: productivity and procurement savings, premiumisation of product mix (shift to actives and speciality intermediates), and targeted pricing.
• Sustainability premium: investments in bio-based feedstocks, reduced carbon footprint and circularity initiatives that support differentiated pricing and regulatory alignment.